December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

78.78 +2.32 (+3.03%)
Streaming Delayed Price Updated: 11:29 AM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth... 
Via Chartmill
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
PTC Therapeutics (PTCT) Q1 2025 Earnings Call ↗
Via The Motley Fool
News headline image
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? ↗
PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
These stocks that are showing activity before the opening bell on Monday. ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder ↗
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review. 
Via Benzinga
News headline image
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July ↗
PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025. 
Via Benzinga
News headline image
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.